Zwahlen C H, Lucroy M D, Kraegel S A, Madewell B R
Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis 95616-8734, USA.
J Am Vet Med Assoc. 1998 Oct 15;213(8):1144-9.
To determine clinical and pathologic findings in cats with alimentary malignant lymphoma and results of treatment with a combination of prednisone, L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and methotrexate.
Retrospective study.
21 cats with alimentary malignant lymphoma.
Medical records were reviewed, and information on signalment, clinical history and signs, previous treatments, and results of laboratory tests, thoracic radiography, and abdominal ultrasonography were obtained.
Test results in all cats were negative for FeLV; 3 of 19 were positive for feline immunodeficiency virus. Thirteen tumors were stage III, 7 were stage IV, and 1 was stage V. Diagnosis was confirmed on the basis of microscopic examination of histologic (n = 13) or cytologic (8) specimens. Immunophenotyping was performed on 13 tumors; 10 were T-cell and 3 were B-cell lymphomas. Overall median duration of first remission was 20 weeks. Overall median survival time was 40 weeks. The only factor significantly associated with duration of first remission was whether cats had a complete response following induction chemotherapy; duration of first remission was significantly associated with survival time. Cats tolerated treatment well; only 1 cat had a delay in the treatment schedule because of neutropenia.
Use of a multidrug chemotherapeutic protocol that includes L-asparaginase and doxorubicin results in minimal adverse effects and prolonged survival times in cats with alimentary malignant lymphoma.
确定患有消化道恶性淋巴瘤的猫的临床和病理特征，以及泼尼松、L-天冬酰胺酶、长春新碱、环磷酰胺、阿霉素和甲氨蝶呤联合治疗的效果。
回顾性研究。
21只患有消化道恶性淋巴瘤的猫。
查阅病历，获取有关动物特征、临床病史和体征、既往治疗情况以及实验室检查、胸部X光和腹部超声检查结果的信息。
所有猫的检测结果显示猫白血病病毒（FeLV）均为阴性；19只中有3只猫免疫缺陷病毒检测呈阳性。13个肿瘤为III期，7个为IV期，1个为V期。根据组织学（n = 13）或细胞学（8）标本的显微镜检查确诊。对13个肿瘤进行了免疫表型分析；10个为T细胞淋巴瘤，3个为B细胞淋巴瘤。首次缓解的总体中位持续时间为20周。总体中位生存时间为40周。与首次缓解持续时间显著相关的唯一因素是猫在诱导化疗后是否有完全缓解；首次缓解持续时间与生存时间显著相关。猫对治疗耐受性良好；只有1只猫因中性粒细胞减少而延迟了治疗计划。
使用包含L-天冬酰胺酶和阿霉素的多药化疗方案对患有消化道恶性淋巴瘤的猫产生的不良反应最小，且能延长其生存时间。
